CA2857939A1 - Anticorps pour le recepteur 3 du facteur de croissance epidermique (her3) dirige contre le domaine iii et le domaine iv d'her3 - Google Patents

Anticorps pour le recepteur 3 du facteur de croissance epidermique (her3) dirige contre le domaine iii et le domaine iv d'her3 Download PDF

Info

Publication number
CA2857939A1
CA2857939A1 CA2857939A CA2857939A CA2857939A1 CA 2857939 A1 CA2857939 A1 CA 2857939A1 CA 2857939 A CA2857939 A CA 2857939A CA 2857939 A CA2857939 A CA 2857939A CA 2857939 A1 CA2857939 A1 CA 2857939A1
Authority
CA
Canada
Prior art keywords
her3
seq
antibody
fragment
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2857939A
Other languages
English (en)
Inventor
Winfried Elis
Seth Ettenberg
Andrew Paul Garner
Nicole Haubst
Heather Huet
Christian Carsten Silvester Kunz
Elizabeth Anne Reisinger Sprague
Qing SHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2857939A1 publication Critical patent/CA2857939A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
CA2857939A 2011-12-05 2012-12-04 Anticorps pour le recepteur 3 du facteur de croissance epidermique (her3) dirige contre le domaine iii et le domaine iv d'her3 Abandoned CA2857939A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05
US61/566,912 2011-12-05
PCT/IB2012/056956 WO2013084151A2 (fr) 2011-12-05 2012-12-04 Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine iii et le domaine iv d'her3

Publications (1)

Publication Number Publication Date
CA2857939A1 true CA2857939A1 (fr) 2013-06-13

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2857939A Abandoned CA2857939A1 (fr) 2011-12-05 2012-12-04 Anticorps pour le recepteur 3 du facteur de croissance epidermique (her3) dirige contre le domaine iii et le domaine iv d'her3

Country Status (16)

Country Link
EP (1) EP2788381A2 (fr)
JP (1) JP2015500830A (fr)
KR (1) KR20140099315A (fr)
CN (1) CN104093742A (fr)
AR (1) AR089085A1 (fr)
AU (1) AU2012349739A1 (fr)
BR (1) BR112014013495A2 (fr)
CA (1) CA2857939A1 (fr)
EA (1) EA201491120A1 (fr)
IL (1) IL232950A0 (fr)
IN (1) IN2014CN04374A (fr)
MX (1) MX2014006731A (fr)
SG (1) SG11201402784WA (fr)
TW (1) TW201331225A (fr)
UY (1) UY34488A (fr)
WO (1) WO2013084151A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301147A (en) * 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
CN107257691B (zh) 2014-07-16 2021-09-21 达娜-法勃肿瘤研究所公司 低级别浆液性卵巢癌中的her3抑制
CN104530237B (zh) * 2014-12-31 2017-09-05 百泰生物药业有限公司 抗Her1的治疗性抗体
LT3365373T (lt) 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
JP6729926B2 (ja) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法
MX2019002664A (es) * 2016-09-15 2019-09-26 Univ Stuttgart Proteina de union a antigeno contra her3.
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2018182422A1 (fr) 2017-03-31 2018-10-04 Merus N.V. Anticorps bispécifiques de liaison à l'erbb-2 et erbb-3 destinés à être utilisés dans le traitement des cellules (f) qui présentent un gène de fusion (nrg1)
TW201910354A (zh) 2017-08-09 2019-03-16 荷蘭商美勒斯公司 結合表皮生長因子受體(EGFR)及cMET的抗體

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP2012525432A (ja) * 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
PT2719708T (pt) * 2009-11-13 2018-01-16 Daiichi Sankyo Europe Gmbh Material e métodos para tratamento ou prevenção de doenças associadas a her-3
ES2566602T3 (es) * 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
PL2707391T3 (pl) * 2011-05-13 2018-04-30 Gamamabs Pharma Przeciwciała przeciwko her3
EP2736928B1 (fr) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Proteines "sur"-liantes dirigees contre erbb3

Also Published As

Publication number Publication date
BR112014013495A8 (pt) 2017-06-13
TW201331225A (zh) 2013-08-01
SG11201402784WA (en) 2014-06-27
MX2014006731A (es) 2015-06-04
WO2013084151A3 (fr) 2014-01-03
AR089085A1 (es) 2014-07-30
IL232950A0 (en) 2014-07-31
WO2013084151A2 (fr) 2013-06-13
CN104093742A (zh) 2014-10-08
EA201491120A1 (ru) 2015-07-30
BR112014013495A2 (pt) 2017-06-13
EP2788381A2 (fr) 2014-10-15
IN2014CN04374A (fr) 2015-09-04
JP2015500830A (ja) 2015-01-08
AU2012349739A1 (en) 2014-06-26
UY34488A (es) 2013-07-31
KR20140099315A (ko) 2014-08-11

Similar Documents

Publication Publication Date Title
US20210008201A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)
US20190194347A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)
US20130273029A1 (en) Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CA2857939A1 (fr) Anticorps pour le recepteur 3 du facteur de croissance epidermique (her3) dirige contre le domaine iii et le domaine iv d'her3

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161205